Clinical Trial Update: Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol [Phase 2]

View source ↗

Summary

A Phase 2 trial assessed how resveratrol influences intestinal and hepatic lipoprotein secretion in individuals with dyslipidemia and insulin resistance; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Insulin Resistance

Drugs mentioned

• Resveratrol (resveratrol)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Dyslipidaemia, Insulin Resistance | Phase 2 | Status: COMPLETED